Systemic / RTI regulatory T cell level or activity reduction for the treatment of a disease or impairment of the CNS

摘要

This disclosure discloses pharmaceutical compositions comprising an active ingredient that reduces the level of systemic immunosuppression and is used to treat a disease, disorder, condition or injury of the CNS in an individual. The pharmaceutical composition is administered in a dose regimen comprising at least one treatment regimen, wherein each regimen sequence comprises a treatment period followed by an untreated interval period.